TradingKey

Mais detalhes de Ionis Pharmaceuticals Inc Empresa

Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).

Informações da empresa

Código da empresaIONS

Nome da EmpresaIonis Pharmaceuticals Inc

Data de listagemMay 17, 1991

CEODr. Brett P. Monia, Ph.D.

Número de funcionários1069

Tipo de títulosOrdinary Share

Fim do ano fiscalMay 17

Endereço2855 Gazelle Court

CidadeCARLSBAD

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal92010

Telefone17609319200

Sitehttps://www.ionis.com/

Código da empresaIONS

Data de listagemMay 17, 1991

CEODr. Brett P. Monia, Ph.D.

Executivos da empresa

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Brett P. Monia, Ph.D.

Chief Executive Officer, Director

179.82K

-0.64%

Dr. Spencer R. Berthelsen, M.D.

Independent Director

156.08K

+2.68%

Ms. Elizabeth L. Hougen

Chief Financial Officer, Executive Vice President - Finance

110.50K

-0.03%

Dr. Richard S. Geary, Ph.D.

Executive Vice President, Chief Development Officer

89.49K

-10.05%

Mr. Patrick R. O'Neil, Esq.

Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary

56.80K

--

Mr. Brian Birchler

Executive Vice President, Chief Business Officer

56.66K

+2.15%

Dr. Eric E. Swayze, Ph.D.

Executive Vice President - Research

48.55K

+0.86%

Mr. Eugene Schneider, M.D.

Executive Vice President, Chief Clinical Development and Operations Officer

47.47K

-16.75%

Dr. Joseph Loscalzo, M.D., Ph.D.

Independent Chairman of the Board

36.33K

+12.65%

Ms. Shannon L. Devers

Chief Human Resources Officer, Executive Vice President

15.94K

+101.50%

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Brett P. Monia, Ph.D.

Chief Executive Officer, Director

179.82K

-0.64%

Dr. Spencer R. Berthelsen, M.D.

Independent Director

156.08K

+2.68%

Ms. Elizabeth L. Hougen

Chief Financial Officer, Executive Vice President - Finance

110.50K

-0.03%

Dr. Richard S. Geary, Ph.D.

Executive Vice President, Chief Development Officer

89.49K

-10.05%

Mr. Patrick R. O'Neil, Esq.

Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary

56.80K

--

Mr. Brian Birchler

Executive Vice President, Chief Business Officer

56.66K

+2.15%

Detalhamento da receita

Moeda: USDAtualizado em: ter, 4 de mar

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

R&D revenue under collaborative agreements

364.56M

49.99%

SPINRAZA royalties

286.58M

39.30%

Product sales, net

70.00M

9.60%

Licensing and other Royalty revenue

8.12M

1.11%

Sem dados

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

R&D revenue under collaborative agreements

364.56M

49.99%

SPINRAZA royalties

286.58M

39.30%

Product sales, net

70.00M

9.60%

Licensing and other Royalty revenue

8.12M

1.11%

Distribuição de ações

Atualizado em: sáb, 16 de ago

Investidores

Tipos de investidores

Investidores

Proporção

Fidelity Management & Research Company LLC

14.83%

The Vanguard Group, Inc.

10.47%

T. Rowe Price Investment Management, Inc.

10.07%

Capital World Investors

7.87%

BlackRock Institutional Trust Company, N.A.

5.47%

Outro

51.29%

Investidores

Proporção

Fidelity Management & Research Company LLC

14.83%

The Vanguard Group, Inc.

10.47%

T. Rowe Price Investment Management, Inc.

10.07%

Capital World Investors

7.87%

BlackRock Institutional Trust Company, N.A.

5.47%

Outro

51.29%

Tipos de investidores

Investidores

Proporção

Investment Advisor

71.14%

Hedge Fund

16.49%

Investment Advisor/Hedge Fund

16.46%

Research Firm

2.04%

Private Equity

1.59%

Pension Fund

1.12%

Individual Investor

0.81%

Bank and Trust

0.66%

Sovereign Wealth Fund

0.28%

Participação acionária institucional

Atualizado em: ter, 1 de jul

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q2

801

185.40M

116.34%

+8.33M

2025Q1

826

174.18M

109.45%

-1.97M

2024Q4

819

166.51M

104.84%

-2.69M

2024Q3

814

162.85M

103.55%

+6.60M

2024Q2

810

149.96M

102.64%

-3.87M

2024Q1

792

148.14M

101.63%

-5.27M

2023Q4

782

147.15M

102.53%

-3.26M

2023Q3

763

145.13M

101.24%

-1.40M

2023Q2

770

142.08M

99.29%

+364.04K

2023Q1

825

136.59M

95.51%

-5.80M

Ver Mais

Atividade dos acionistas

Nome

Ações detidas

Proporção

Variação

Var. %

Data

Fidelity Management & Research Company LLC

23.61M

14.84%

+924.09K

+4.07%

Mar 31, 2025

The Vanguard Group, Inc.

16.35M

10.27%

-88.61K

-0.54%

Mar 31, 2025

T. Rowe Price Investment Management, Inc.

16.18M

10.16%

+323.67K

+2.04%

Mar 31, 2025

Capital World Investors

12.36M

7.77%

+896.58K

+7.82%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

8.90M

5.59%

+21.73K

+0.24%

Mar 31, 2025

Bellevue Asset Management AG

7.85M

4.93%

-15.50K

-0.20%

Mar 31, 2025

Wellington Management Company, LLP

8.42M

5.29%

-255.73K

-2.95%

Mar 31, 2025

Deep Track Capital LP

4.56M

2.87%

+2.63M

+136.01%

Mar 31, 2025

State Street Global Advisors (US)

4.85M

3.04%

-581.28K

-10.71%

Mar 31, 2025

Two Sigma Investments, LP

3.78M

2.37%

+1.51M

+66.38%

Mar 31, 2025

Ver Mais

ETFs Relacionados

Atualizado em: qua, 6 de ago

Nome

Proporção

Tema Neuroscience and Mental Health ETF

3.69%

ARK Genomic Revolution ETF

3.41%

Virtus LifeSci Biotech Products ETF

2.32%

SPDR S&P Biotech ETF

1.56%

WisdomTree BioRevolution Fund

1.35%

Tema Heart & Health ETF

1.08%

Direxion Daily S&P Biotech Bull 3X Shares

1.01%

Capital Group US Small and Mid Cap ETF

0.92%

iShares Health Innovation Active ETF

0.88%

Franklin Genomic Advancements ETF

0.83%

Ver Mais

Tema Neuroscience and Mental Health ETF

Proporção3.69%

ARK Genomic Revolution ETF

Proporção3.41%

Virtus LifeSci Biotech Products ETF

Proporção2.32%

SPDR S&P Biotech ETF

Proporção1.56%

WisdomTree BioRevolution Fund

Proporção1.35%

Tema Heart & Health ETF

Proporção1.08%

Direxion Daily S&P Biotech Bull 3X Shares

Proporção1.01%

Capital Group US Small and Mid Cap ETF

Proporção0.92%

iShares Health Innovation Active ETF

Proporção0.88%

Franklin Genomic Advancements ETF

Proporção0.83%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações

Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados

Ionis Pharmaceuticals Inc

42.660USD

Ionis Pharmaceuticals Inc

42.660

Visão Geral

Empresa

Serviços Financeiros